Sugi Predict

Sugi Predict / Compounds / SCHEMBL5496809

SCHEMBL5496809

SCHEMBL5496809

CNc1cccc(CN2CCN(C)CC2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 1/20 0.59
▸ BTK Q06187 1/20 0.49
▸ CHKA P35790 4/20 0.49
▸ HRH3 Q9Y5N1 1/20 0.48
▸ LMNA P02545 2/20 0.47
▸ JAK2 O60674 2/20 0.47
▸ JAK3 P52333 2/20 0.47
▸ PTK2 Q05397 1/20 0.47
▸ CA2 P00918 1/20 0.46
▸ NCF1 P14598 1/20 0.46
▸ PRMT6 Q96LA8 1/20 0.46
▸ SIGMAR1 Q99720 2/20 0.46
▸ ACP1 P24666 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ HDAC3 O15379 1/20 0.45
▸ HDAC4 P56524 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC7 Q8WUI4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28175640 0.87 ALDH1A1 (0.56) LMNAPRMT6SIGMAR1NPC1TP53
SCHEMBL922710 0.87 PRMT6 (0.57) HRH3NCF1PRMT6
SCHEMBL14622108 0.86 SIGMAR1 (0.53) MC4RHRH3SIGMAR1
SCHEMBL6736373 0.85 SMN1; SMN2 (0.58) HRH3NCF1PRMT6
SCHEMBL13535291 0.84 MC4R (0.74) MC4RCHKAHRH3LMNACA2
SCHEMBL13490043 0.83 MEN1 (0.60) ACP1
SCHEMBL28855158 0.83 SIGMAR1 (0.57) HRH3SIGMAR1ACP1
SCHEMBL4367879 0.83 NCF1 (0.60) HRH3LMNAJAK2JAK3PTK2
SCHEMBL13853605 0.82 BTK (0.57) MC4RBTKNPC1TP53RAB9A
SCHEMBL15000060 0.81 BTK (0.59) MC4RBTKLMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119866333-A KIT inhibitors, compounds, pharmaceutical compositions, and methods of use thereof 亚力维克希斯股份有限公司 2025-04-22 — — CN disclosed
US-20250066355-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2025-02-27 — — US disclosed
US-12172998-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-12-24 — — US disclosed
WO-2024029489-A1 KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF MODULUS DISCOVERY, INC. (JP) 2024-02-08 — — WO disclosed
CN-114805341-B Aromatic heterocyclic compound, and preparation method and application thereof 上海翊石医药科技有限公司 2023-12-08 — — CN disclosed
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2023-04-20 — — US disclosed
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2023-04-20 — — US disclosed
US-11535616-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC (US) 2022-12-27 — — US disclosed
US-11535616-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC (US) 2022-12-27 — — US disclosed
EP-3453710-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-09-21 — — EP disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed
US-20160083379-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-03-24 — — US disclosed
WO-2016044429-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2016-03-24 — — WO disclosed
US-20160083379-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-03-24 — — US disclosed
US-20160083379-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-03-24 — — US disclosed
WO-2016044429-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2016-03-24 — — WO disclosed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 — — EP disclosed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A MC4R 3477/4885BTK 2988/4885CHKA 894/4885
US-12172998-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5C MC4R 3535/4885BTK 3026/4885CHKA 879/4885
US-20160083379-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C MC4R 3535/4885BTK 3026/4885CHKA 879/4885
US-11535616-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5C MC4R 3535/4885BTK 3026/4885CHKA 879/4885
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C MC4R 3535/4885BTK 3026/4885CHKA 879/4885
US-20250066355-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C MC4R 3535/4885BTK 3026/4885CHKA 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.